按肿瘤类型划分的癌症患者临床试验点：clinicaltrials.gov上的癌症试验项目组合
Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov.
作者信息
Prasad Vinay, Goldstein Jeffery A
机构信息
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Dr. 10/12N226, Bethesda, MD 20892, United States.
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
出版信息
Eur J Cancer. 2015 Nov;51(17):2718-23. doi: 10.1016/j.ejca.2015.07.045. Epub 2015 Aug 25.
BACKGROUND
Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes.
METHODOLOGY
We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers.
RESULTS
From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrollment varied by tumour type, with both over and under-representation occurring.
CONCLUSION
Opportunities to enroll in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.
背景
尽管参与癌症临床试验的比例较低，但对于可用临床试验的数量以及患者的空位情况却知之甚少。此外，尚不清楚临床试验空位与癌症亚型的发病率和死亡率之间存在何种关系。
方法
我们按癌症（肿瘤）类型确定了在clinicaltrials.gov上注册的I期、II期和III期试验的数量。所有计数均为过去5年（2008 - 2013年）的数据。我们将这些计数与监测、流行病学和最终结果（SEER）数据库报告的32种常见癌症的疾病发病率和患病率进行了比较。
结果
2008年至2013年期间，clinicaltrials.gov上注册了3879项关于癌症亚型的I期试验、4982项II期试验和1379项III期试验。这些试验累计计划招募的患者分别为203,396名、421,502名和697,787名。试验入组情况因肿瘤类型而异，既有入组人数过多的情况，也有入组人数不足的情况。
结论
参与临床试验的机会因阶段和肿瘤类型而异。肿瘤学家必须继续致力于临床试验。
Zotero 插件